Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | S-49076 |
Synonyms | |
Therapy Description |
S-49076 is a multi-kinase inhibitor that inhibits wild-type and mutant forms of MET and FGFR1-2, as well as FGFR3, AXL, MER, and AURKB, resulting in decreased downstream signaling, and potentially resulting in decreased tumor growth (PMID: 23804704, PMID: 28624695, PMID: 28619752). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
S-49076 | S49076 | Aurkb Inhibitors 21 AXL Inhibitor 30 FGFR1 Inhibitor 28 FGFR2 Inhibitor 23 FGFR3 Inhibitor 19 MET Inhibitor 59 | S-49076 is a multi-kinase inhibitor that inhibits wild-type and mutant forms of MET and FGFR1-2, as well as FGFR3, AXL, MER, and AURKB, resulting in decreased downstream signaling, and potentially resulting in decreased tumor growth (PMID: 23804704, PMID: 28624695, PMID: 28619752). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FGFR3 act mut | urinary bladder cancer | predicted - sensitive | S-49076 | Preclinical | Actionable | In a preclinical study, S-49076 inhibited autophosphorylation of FGFR3 and downstream signaling in bladder cancer cells over expressing constitutively active FGFR3 in culture (PMID: 23804704). | 23804704 |
FGFR2 act mut | stomach carcinoma | sensitive | S-49076 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, S-49076 inhibited Met activation, resulting in growth inhibition of gastric carcinoma cells harboring FGFR2 activating mutations in culture and in cell line xenograft models (PMID: 23804704). | 23804704 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|